

Case Report

Basal cell carcinoma superimposed on a cutaneous leishmaniasis lesion in an immunocompromised patient

Ali Asilian¹, Iman Momeni², Parastou Khosravan²

Abstract

Leishmaniasis is a protozoan infection due to organisms of the genus *Leishmania*. The differential diagnosis of cutaneous leishmaniasis includes arthropod bites, basal cell carcinoma (BCC) and other malignancies. BCC is the most common form of skin cancer. We present a case of cutaneous leishmaniasis resistant to standard intralesional glucantime injection in an immunocompromised patient, which was proved to be BCC after surgical excision.

KEYWORDS: Leishmaniasis, Basal Cell Carcinoma, Glucantime.

J Res Med Sci 2012; 17(1): 108-110

Leishmaniasis is a protozoan infection whose diagnosis should be confirmed by the presence of the organism in dermal macrophages in skin biopsy, dermal scrapings and fine-needle aspirate (FNA). The differential diagnosis of cutaneous leishmaniasis includes arthropod bites, atypical mycobacteriosis, basal cell carcinoma (BCC) and other malignancies. Local therapy consists of excision, laser ablation,¹ cryotherapy,² local heat, electrotherapy, and local and intralesional drug administration.^{3,4} BCC is the most frequent skin cancer. Sun exposure and anatomic site appear to be important in the etiology of BCC. It may also arise in burn or vaccination scars.

Case Report

In 2009, a 52-year-old woman presented with a single lesion on her nose, which started as a papule, referred to Sedighe Tahereh Clinic, Isfahan, Iran. The lesion had existed for a period of 14 months and was slowly increasing in size, enlarging to a plaque. The diagnosis of leishmaniasis was confirmed with a positive smear of the lesion showing leishmania bodies about 1 year before. All five members of her

family had had a history of proven leishmaniasis. In the past medical history, the patient was a renal failure case since 11 years before and received a renal transplant 4 years after the diagnosis of renal failure. She was also suffering from hypertension and hyperlipidemia. She was receiving oral mycophenolate mofetil (2 g daily) and cyclosporine (100 mg daily). Her skin type was determined as IV in the skin examination. No actinic keratosis was present. A 3×3 cm indurated ulcer with elevated borders was present on the tip of her nose (Figure 1). Her therapeutic plan was intralesional glucantime injection (approximately 1 ml of 1.5 g vial per week, intralesional injection). After completing a therapeutic course of 20 sessions receiving intralesional glucantime injections, she was considered as glucantime therapy resistant. Therefore, surgical excision was advised and performed under local anesthesia. The histopathology was that of a BCC.

Discussion

The occurrence of malignant neoplasms in sites of scars is an infrequent but well-known phenomenon.⁵ Although the coexistence of cuta-

1- Professor, Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

2- Resident, Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Corresponding author: Iman Momeni

E-mail: imanmomeni@resident.mui.ac.ir



Figure 1. Superimposed basal cell carcinoma on a leishmaniasis lesion

neous leishmaniasis and BCC may have been coincidental, some studies suggest that an association between these two entities does exist.⁶ Leishmaniasis can directly or indirectly alter the diagnosis and course of different malignancies.⁷ There are reports of BCC in chronic leg ulcers.⁸ Cases of BCC developing in a *Leishmania* scar have also been documented,⁹ but to our knowledge, cases of both leishmaniasis and BCC in the same site and the same lesion are rare.¹⁰ However, in this case, solid organ transplantation and long term immuno-

suppressive therapy should be considered as risk factors for malignancy. Advances in effective immunosuppression after organ transplantation have led to increased risk of malignancies, particularly skin cancers¹¹ including squamous cell carcinoma, basal BCC and malignant melanoma.¹² Thus, malignancies should be considered in the differential diagnosis of leishmaniasis lesions difficult to treat. The possible role of cutaneous leishmaniasis, as a predisposing factor for skin cancer, should also be kept in mind.

Conflict of Interests

Authors have no conflict of interests.

Authors' Contributions

AA was the main therapeutic physician and helped write the manuscript. IM and PK contributed in writing the manuscript. All authors have read and approved the content of the manuscript.

References

1. Asilian A, Sharif A, Faghihi G, Enshaeieh S, Shariati F, Siadat AH. Evaluation of CO laser efficacy in the treatment of cutaneous leishmaniasis. *Int J Dermatol* 2004; 43(10): 736-8.
2. Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini HA. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. *Ann Trop Med Parasitol* 2003; 97(5): 493-8.
3. Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. *Clin Exp Dermatol* 2006; 31(5): 634-7.
4. Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Oliario P. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. *Am J Trop Med Hyg* 1995; 53(6): 648-51.
5. Bartle EJ, Sun JH, Wang XW, Schneider BK. Cancers arising from burn scars. A literature review and report of twenty-one cases. *J Burn Care Rehabil* 1990; 11(1): 46-9.
6. Morsy TA, Mangoud AM, el-Sebai MM, al Seghayer SM. Cutaneous leishmaniasis as a possible predisposing factor for skin malignancy. *J Egypt Soc Parasitol* 1992; 22(3): 599-602.
7. Kopterides P, Mourtzoukou EG, Skopelitis E, Tsavaris N, Falagas ME. Aspects of the association between leishmaniasis and malignant disorders. *Trans R Soc Trop Med Hyg* 2007; 101(12): 1181-9.
8. Granel F, Barbaud A, Schmutz JL. Basal and squamous cell carcinoma associated with chronic venous leg ulcer. *Int J Dermatol* 2001; 40(8): 539-40.
9. Aziz Jalali MH, Ansarin H, Mirzazadeh Javaheri S. Basal cell carcinoma superimposed on an old scar of localized cutaneous Leishmaniasis: A case report. *Iran J Dermatol* 2004; 7(27): 192-4.
10. Morsy TA, Mangoud AM, al Seghayer SM. Cutaneous leishmaniasis and basal cell carcinoma in a patient from Al Baha, Saudi Arabia. *J Egypt Soc Parasitol* 1992; 22(1): 167-70.
11. Lumbang W, Stasko T. Management of skin cancer after organ transplantation. *G Ital Dermatol Venereol* 2011; 146(5): 341-52.
12. DePry JL, Reed KB, Cook-Norris RH, Brewer JD. Iatrogenic immunosuppression and cutaneous malignancy. *Clin Dermatol* 2011; 29(6): 602-13.